Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Subscribe
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Subscribe
FREE
Hepatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Diagnosis of progressive familial intrahepatic cholestasis in adulthood
6
Mins
September 2024
Progressive familial intrahepatic cholestasis (PFIC) is a cholestatic condition that typically arises in childhood. As such, if an adult…
Read more
10
Mins
7th March 2022
The Challenging Ethical Landscape of NAFLD
Management of NAFLD is not as straightforward as it first looks. There is no virus to suppress, no single behaviour to modify, no easy prescription, and no straightforward route to transplantation.
14
Mins
3rd February 2022
Optimising Cholangiocarcinoma Diagnosis and Treatment Focusing on Precision Medicine
This article is based on interviews conducted with Lorenza Rimassa, Arndt Vogel, and Harpreet Wasan. They provided their expert opinion…
6
Mins
13th January 2022
New Data on Aramchol™: Efficacy of a Higher Daily Exposure to Aramchol on Fibrosis Improvement in the ARMOR Study Open-Label Part
Non-alcoholic steatohepatitis (NASH) is the advanced form of non-alcoholic fatty liver disease, which can lead to further…
12
Mins
21st September 2021
Using Innovation to Develop Digital Tools for Public Health During the COVID-19 Pandemic
This paper describes a case study of the co-design and development of two new COVID-19 digital services to support the Scottish…
8
Mins
21st September 2021
Liver Transplantation in Patients with Acute-on-Chronic Liver Failure: Challenging the Limits
The natural history of patients with cirrhosis is characterised by the development of acute decompensating events…
12
Mins
21st September 2021
Hepatic Manifestations of Lysosomal Storage Disorders: Differential Diagnosis, Investigations, and Treatment, Current and Upcoming
Hepatomegaly can be a presenting or associated feature of an inherited lysosomal storage disorder. Thus, a high index of suspicion should be maintained in patients without an aetiologic diagnosis. Read more.
14
Mins
21st September 2021
Portal Hypertension in Non-alcoholic Fatty Liver Disease in the Era of Non-invasive Assessment
Non-alcoholic fatty liver disease (NAFLD) is considered as one of the fastest emerging global health priorities due to the continuous…
6
Mins
21st September 2021
Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use
The benefits of rifaximin use continues to gather momentum, given its well-tolerated side-effect profile, and these require consideration.
Loading posts...
« Previous
1
2
3
4
5
6
…
17
Next »